LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Teladoc Health, Inc. investors (“Teladoc” or the “Company”) (NYSE: TDOC) concerning the Company and its officers’ possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
On December 5, 2018, the Southern Investigative Research Foundation (“SIRF”) published an article alleging that Teladoc’s Chief Financial Officer provided trading advice to a junior employee regarding Teladoc securities, telling her “when he thought there were good opportunities to sell some shares.” On this news, Teladoc’s share price fell more than 10%, closing at $55.81 per share on December 6, 2018, thereby injuring investors.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased Teladoc securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
